. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Antibodies, Monoclonal, Humanized/administration & dosageAntibodies, Monoclonal, Humanized/adverse effectsAntineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useCarboplatin/administration & dosageCarboplatin/adverse effectsCarcinoma, Non-Small-Cell Lung/chemistryCarcinoma, Non-Small-Cell Lung/drug therapyCarcinoma, Non-Small-Cell Lung/pathologyCarcinoma, Non-Small-Cell Lung/therapyCetuximabChemoradiotherapy/adverse effectsConsolidation ChemotherapyDisease-Free SurvivalErbB Receptors/antagonists & inhibitorsErbB Receptors/immunologyEsophagitis/etiologyFemaleHumansLung Neoplasms/chemistryLung Neoplasms/drug therapyLung Neoplasms/pathologyLung Neoplasms/therapyMaleNeoplasm Proteins/antagonists & inhibitorsNeoplasm Proteins/immunologyPaclitaxel/administration & dosagePaclitaxel/adverse effectsProtein Kinase Inhibitors/administration & dosageProtein Kinase Inhibitors/adverse effectsRadiation Injuries/etiologyRadiotherapy DosageSurvival Analysis
Substances: See more » Antibodies, Monoclonal, HumanizedNeoplasm ProteinsProtein Kinase InhibitorsCarboplatinEGFR protein, humanErbB ReceptorsPaclitaxelCetuximab
Year: 2014 PMID: 24852394
Source DB: PubMed Journal: Clin Adv Hematol Oncol ISSN: 1543-0790